Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights

Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® whole transcriptomic analysis in Black women

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – April 27, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced it will present new data from ongoing clinical research evaluating its comprehensive genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place June 3-7, 2022 in Chicago, Illinois.

Data will highlight Agendia’s clinical focus on whole transcriptome analysis as well as breast cancer care for underserved populations, in addition to several sub-studies derived from the company’s FLEX Registry, the real-world, multicenter, prospective, observational breast cancer study. Two abstracts selected by ASCO for oral discussion will feature an investigation of the ImPrint genomic test, currently for research use only, from the I-SPY trial series and an analysis from FLEX of hormone receptor-positive breast cancer in Black women classified by BluePrint®.

The company believes the FLEX Registry’s approach to cancer research is accelerating impactful data generation, aimed at redefining cancer care. Its patient-centric design and national network of participating sites is backed by Agendia’s infrastructure, allowing its investigator-initiated sub-studies to produce important results that have the potential to drive science forward, like those being shared at ASCO 2022.

Following are details of the nine Agendia abstracts that have been accepted for poster discussion or poster sessions at the ASCO 2022 Annual Meeting:

Poster discussion sessions:

  • The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2
    • Authors: Kuilman, MM., et al.
    • Presenter: Lorenza Mittempergher, PhD | Research and Development, Agendia NV
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT
    • Abstract #: 514
  • Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint
    • Authors: Reid, S., et al.
    • Presenter: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Poster Discussion: Monday, June 6, 2022 | 1:15 PM-2:45 PM CDT
    • Abstract #: 517

Poster sessions:

  • Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial
    • Authors: Socoteanu, M., et al.
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: 556
  • Clinical implications for patients with discordant oncotype and MammaPrint results
    • Authors: Socoteanu, M., et al.
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: 560
  • Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer
    • Authors: Nasrazadani, A., et al.
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: 559
  • Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy
    • Authors: Chung, A., et al.
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: 585
  • Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 trial and FLEX Registry
    • Authors: Cha, J., et al.
    • Session: Breast Cancer – Local/Regional/Adjuvant
    • Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: 592
  • FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data
    • Authors: Ma, C., et al.
    • Session: TBC
    • Session Date & Time: Monday, June 6, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: TPS612
  • Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study
    • Authors: Sivapiragasam, A., et al.
    • Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
    • Session Date & Time: Sunday, June 5, 2022 | 8:00 AM-11:00 AM CDT
    • Abstract #: 3134

Agendia will be sharing important updates on its Twitter, Facebook and LinkedIn pages throughout the conference. The event program can be found at the ASCO 2022 website.

About Agendia

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

Media Contacts

Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com